AFP and hepatocellular carcinoma: Following a previous trial (REACH), in which benefit in comparison with placebo was only seen in a subgroup of patients with AFP ≥400 ng/mL,23, 60 data from the double‐blind phase 3 trial REACH‐2, including only patients with AFP ≥400 ng/mL at baseline (N=292, randomized 2:1 to ramucirumab or placebo), provided the basis for the European Medicines Agency and FDA approval of ramucirumab to treat this subgroup of patients with advanced HCC who switched from sorafenib.61